


## ABOUT

» An estimated **50%** of the worldwide population **is infected with *H. pylori***.
» *H. pylori* is the leading cause of peptic ulcer disease and if untreated, can lead to gastric cancer.


## WHY

» **Proprietary strain:** Pylopass® *is a Lactobacillus reuteri DSMZ 17648*, which specifically binds and coaggregates with *H. pylori* to reduce the bacterial load.
» **Efficiency:** Pylopass® decrease the risk of developing gastritis and peptic ulcer disease and can increase the efficacy of Antibiotics treatment.
» **No side effects:** Pylopass® does not alter the microflora of the gut and does not contribute to the antibiotic resistance.


## POSOLOGY **200mg** once daily.

## CLINICAL STUDIES

Monotherapy of Pylopass® can lead to an eradication of *H. pylori* [1]





Pylopass® supplementation significantly reduces *H. pylori* load [2-4]




**Reduction of *H. pylori* load in 60% of the subjects in only 2 weeks[2].**

**Efficacy and safety confirmed by different studies in different countries (n=570).**

» Reduction of *H. pylori* load in all cases.
» Eradication (in 10% - 50% of the subjects).
» Improvement of the symptoms.





***Pylopass® helps to decrease symptoms associated with a Gastritis after 14 days.***

Decrease of the severity of the symptoms on a 3 points scale: improvement of quality of life.

### Patented Mechanism of Action

Pylopass® is able to recognize surface structures on *H. pylori* and to form co-aggregates. Those Co-aggregates are eliminated from the organism through the gastrointestinal tract. This leads to a reduction of *Helicobacter pylori* load in the stomach.



Scanning electron microscopy of coaggregates of Pylopass® (blue) and *Helicobacter pylori* (red), 1,800 x magnification.

one HEALTH Pylopass®

**1.** Uspienskiy et al (2016) Gastroenterology 2016. **2.** Mehling H & Busjahn A (2013). Nutrients 5: 3062-3072. **3.** Holz C. et al (2014). Probiotics & Antimicro. Prot. 7: 91-100. **4.** Bordin DS et al. (2016). THERAPIST, 5